期刊
TRANSLATIONAL RESEARCH
卷 232, 期 -, 页码 13-36出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.12.007
关键词
-
资金
- Colton Center for Autoimmunity, NIH [AR060861, AR057781, AR065964, AI071651]
- Lupus Research Foundation
- Lupus Research Alliance
- EMD Serono
- Janssen, Inc.
In light of the COVID-19 pandemic, assessing its impact on patients with autoimmune rheumatic diseases, specifically systemic lupus erythematosus, is crucial. Patients with SLE present unique considerations due to their use of immunosuppressants and potential susceptibility factors like organ damage from SLE. Research on SLE may offer insights into immune responses seen in severe cases of COVID-19.
As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a growing need to assess its impact in patients with autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). Patients with SLE are a unique population when considering the risk of contracting COVID-19 and infection outcomes. The use of systemic glucocorticoids and immunosuppressants, and underlying organ damage from SLE are potential susceptibility factors. Most patients with SLE have evidence of high type I interferon activity, which may theoretically act as an antiviral line of defense or contribute to the development of a deleterious hyperinflammatory response in COVID-19. Other immunopathogenic mechanisms of SLE may overlap with those described in COVID-19, thus, studies in SLE could provide some insight into immune responses occurring in severe cases of the viral infection. We reviewed the literature to date on COVID-19 in patients with SLE and provide an in-depth review of current research in the area, including immune pathway activation, epidemiology, clinical features, outcomes, and the psychosocial impact of the pandemic in those with autoimmune disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据